Patents by Inventor Zhi-Liang Wei

Zhi-Liang Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12168648
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: December 17, 2024
    Assignee: EPIODYNE, INC.
    Inventors: Julio Cesar Medina, Alok Nerurkar, Corinne Sadlowski, Frederick Seidl, Heng Cheng, Jason Duquette, John Lee, Martin Holan, Pingyu Ding, Xiaodong Wang, Tien Widjaja, Thomas Nguyen, Ulhas Bhatt, Yihong Li, Zhi-liang Wei
  • Publication number: 20240092746
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: February 13, 2023
    Publication date: March 21, 2024
    Inventors: Julio Cesar MEDINA, Alok NERURKAR, Corinne SADLOWSKI, Frederick SEIDL, Heng CHENG, Jason DUQUETTE, John LEE, Martin HOLAN, Pingyu DING, Xiaodong WANG, Tien WIDJAJA, Thomas NGUYEN, Ulhas BHATT, Yihong LI, Zhi-liang WEI
  • Patent number: 11634396
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: April 25, 2023
    Assignee: EPIODYNE, INC.
    Inventors: Julio Cesar Medina, Alok Nerurkar, Corinne Sadlowski, Frederick Seidl, Heng Cheng, Jason Duquette, John Lee, Martin Holan, Pingyu Ding, Xiaodong Wang, Tien Widjaja, Thomas Nguyen, Ulhas Bhatt, Yihong Li, Zhi-liang Wei
  • Publication number: 20220356157
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: April 5, 2022
    Publication date: November 10, 2022
    Inventors: Julio Cesar MEDINA, Alok NERURKAR, Corinne SADLOWSKI, Frederick SEIDL, Heng CHENG, Jason DUQUETTE, John LEE, Martin HOLAN, Pingyu DING, Xiaodong WANG, Tien WIDJAJA, Thomas NGUYEN, Ulhas BHATT, Yihong LI, Zhi-liang WEI
  • Patent number: 11352316
    Abstract: Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: June 7, 2022
    Assignee: EPIODYNE, INC.
    Inventors: Julio Cesar Medina, Lawrence R McGee, Zhi-Liang Wei, Corinne Sadlowski, Frederick Seidl, Ulhas Bhatt, Xiaodong Wang, Thomas Nguyen, David Sperandio, Pingyu Ding, Alok Nerurkar, Yihong Li, Jason Duquette
  • Publication number: 20210163402
    Abstract: Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Application
    Filed: July 10, 2020
    Publication date: June 3, 2021
    Inventors: Julio Cesar Medina, Lawrence R McGee, Zhi-Liang Wei, Corinne Sadlowski, Frederick Seidl, Ulhas Bhatt, Xiaodong Wang, Thomas Nguyen, David Sperandio, Pingyu Ding, Alok Nerurkar, Yihong Li, Jason Duquette
  • Publication number: 20210147343
    Abstract: Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulate the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Application
    Filed: April 4, 2019
    Publication date: May 20, 2021
    Inventors: Julio Cesar MEDINA, Larry McGEE, Zhi-Liang WEI, Corinne SADLOWSKI, Frederick SEIDL, Ulhas BHATT, Xiaodong WANG, Thomas NGUYEN, David SPERANDIO, Pingyu DING, Alok NERURKAR, Yihong LI, Jason DUQUETTE
  • Publication number: 20150266822
    Abstract: Compounds are provided according to formula 1: where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Application
    Filed: December 14, 2014
    Publication date: September 24, 2015
    Inventors: Zhi-Liang Wei, Sumithra Gowlugari, Carl Kaub, Zhan Wang, Yeyu Cao, John Kincaid
  • Patent number: 9133122
    Abstract: Compounds are provided according to formula 1: where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: September 15, 2015
    Assignee: EVOTEC AG
    Inventors: Zhi-Liang Wei, Sumithra Gowlugari, Carl Kaub, Zhan Wang, Yeyu Cao, John Kincaid
  • Patent number: 8946439
    Abstract: Compounds are provided according to formula 1: where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: February 3, 2015
    Assignee: Evotec AG
    Inventors: Zhi-Liang Wei, Sumithra Gowlugari, Carl Kaub, Zhan Wang, Yeyu Cao, John Kincaid
  • Publication number: 20140323532
    Abstract: Compounds are provided according to formula 1: where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Application
    Filed: July 9, 2014
    Publication date: October 30, 2014
    Inventors: Zhi-Liang WEI, Sumithra GOWLUGARI, Carl KAUB, Zhan WANG, Yeyu CAO, John KINCAID
  • Patent number: 8653091
    Abstract: Fused heterocyclic compounds are provided according to formula 1a or 1b: where R1, R2, and R3 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: February 18, 2014
    Assignee: Evotec AG
    Inventors: Zhi-Liang Wei, John Kincaid, Michael G. Kelly, Donogh John Roger O'Mahony, Carl Kaub
  • Publication number: 20120149700
    Abstract: Fused heterocyclic compounds are provided according to formula 1: where R1, R2, R3, and m are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Application
    Filed: December 12, 2011
    Publication date: June 14, 2012
    Inventors: Zhi-Liang WEI, Donogh John Roger O'MAHONY, Matthew DUNCTON, John KINCAID, Michael G. KELLY, Zhan WANG
  • Patent number: 8076345
    Abstract: Fused heterocyclic compounds are provided according to formula 1: where R1, R2, R3, and m are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: December 13, 2011
    Assignee: Evotec AG
    Inventors: Zhi-Liang Wei, Donogh John Roger O'Mahony, Matthew Duncton, John Kincaid, Michael G. Kelly, Zhan Wang
  • Patent number: 8030300
    Abstract: One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: October 4, 2011
    Assignees: Georgetown University, The John Hopkins University
    Inventors: Alan P. Kozikowski, John L. Musachio, Kenneth J. Kellar, Yingxian Xiao, Zhi-Liang Wei, Hong Fan
  • Publication number: 20110237578
    Abstract: Compounds are provided according to formula (I), where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Application
    Filed: September 14, 2009
    Publication date: September 29, 2011
    Inventors: Zhi-Liang Wei, Sumithra Gowlugari, Carl Kaub, Zhan Wang, Yeyu Cao, John Kincaid
  • Publication number: 20110065681
    Abstract: Compounds are provided according to formula 1: where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Application
    Filed: February 27, 2009
    Publication date: March 17, 2011
    Inventors: Zhi-Liang Wei, Sumithra Gowlugari, Carl Kaub, Zhan Wang, Yeyu Cao, John Kincaid
  • Publication number: 20110009432
    Abstract: Fused heterocyclic compounds are provided according to formula 1a or 1b: where R1, R2, and R3 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
    Type: Application
    Filed: March 31, 2008
    Publication date: January 13, 2011
    Inventors: Zhi-Liang Wei, John Kincaid, Michael G. Kelly, Donogh John Roger O'Mahony, Carl Kaub
  • Publication number: 20100004222
    Abstract: Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
    Type: Application
    Filed: February 22, 2007
    Publication date: January 7, 2010
    Applicant: Renovis, Inc.
    Inventors: Michael G. Kelly, Carl J. Kaub, John Kincaid, Satyanarayana Janagani, Guoxian Wu, Zhi-Liang Wei, Kiran Sahasrabudhe, Matthew Duncton, Ravindra B. Upasani, Yunfeng Fang, Matthew Cox, Jianhua He
  • Patent number: 7576099
    Abstract: Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: August 18, 2009
    Assignee: Renovis, Inc.
    Inventors: Michael G. Kelly, John Kincaid, Matthew Duncton, Kiran Sahasrabudhe, Satyanarayana Janagani, Ravindra B. Upasani, Guoxian Wu, Jianhua He, legal representative, Zhi-Liang Wei, Carl Kaub, YunFeng Fang